Strategy for Developing a Stable CHO Cell Line that Produces Large Titers of Trastuzumab Antibody

CONCLUSIONS: The current simple workflow ensures strict monoclonality and relatively high production of trastuzumab. This workflow could potentially be implemented in Research and Development (R&D) laboratories, including in developing countries for the production of recombinant monoclonal antibodies in a cost-effective manner.PMID:38163935 | DOI:10.31083/j.fbe1504024

Source: Frontiers in Bioscience - Elite - January 2, 2024 Category: Biomedical Science Authors: Hafsa Boulenouar Nadia Bouchoutrouch Youssef Amar Moulay El Abbes Faouzi Yahia Cherrah Hassan Sefrioui Hassan Ait Benhassou Source Type: research